Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Minister was briefed on the nationwide dengue situation
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
Subscribe To Our Newsletter & Stay Updated